Literature DB >> 24033757

What do we learn from repeated population analyses?

Stephen B Duffull1, Daniel F B Wright.   

Abstract

Population analyses are performed on new and existing drugs. They play an important role in quantifying the time course of drug effects and provide a means of understanding the impact of variability between individuals on dosing requirements. For some drugs there have been several population analyses reported in the literature. It is important to understand how repeated population analyses can value add and what authors and readers can consider when reviewing such analyses. The purpose of this review is to explore what is learnt from repeated population analyses and provide an understanding of how the value-added nature of these analyses can be considered.
© 2013 The British Pharmacological Society.

Keywords:  enoxaparin; population PK

Mesh:

Substances:

Year:  2015        PMID: 24033757      PMCID: PMC4294075          DOI: 10.1111/bcp.12233

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 2.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

5.  Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré; René Bruno
Journal:  Stat Med       Date:  2002-09-30       Impact factor: 2.373

6.  A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.

Authors:  J C Stiekema; J M Van Griensven; T G Van Dinther; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

7.  Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.

Authors:  René Bruno; Pascale Baille; Sylvie Retout; Nicole Vivier; Christine Veyrat-Follet; Ger-Jan Sanderink; Richard Becker; Elliott M Antman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

8.  Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy.

Authors:  C Lebaudy; J S Hulot; Z Amoura; N Costedoat-Chalumeau; R Serreau; A Ankri; J Conard; A Cornet; M Dommergues; J C Piette; P Lechat
Journal:  Clin Pharmacol Ther       Date:  2008-04-23       Impact factor: 6.875

9.  Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.

Authors:  A Berges; S Laporte; M Epinat; P Zufferey; E Alamartine; B Tranchand; H Decousus; P Mismetti
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

10.  Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.

Authors:  Jean-Sébastien Hulot; Clarisse Vantelon; Saïk Urien; Anissa Bouzamondo; Isabelle Mahé; Annick Ankri; Gilles Montalescot; Philippe Lechat
Journal:  Ther Drug Monit       Date:  2004-06       Impact factor: 3.681

View more
  9 in total

1.  External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

Authors:  Chen-Yan Zhao; Zheng Jiao; Jun-Jun Mao; Xiao-Yan Qiu
Journal:  Br J Clin Pharmacol       Date:  2016-02-26       Impact factor: 4.335

2.  Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.

Authors:  Chakradhar V Lagishetty; Stephen B Duffull
Journal:  AAPS J       Date:  2015-06-26       Impact factor: 4.009

3.  Pharmacometrics: so much mathematics and why planes achieve their destinations with almost perfect results ….

Authors:  Geoffrey K Isbister; Robert Bies
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

4.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

5.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

6.  Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.

Authors:  Celeste Bloomfield; Christine E Staatz; Sean Unwin; Stefanie Hennig
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

7.  Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.

Authors:  Jeroen Diepstraten; Esther J H Janssen; Christian M Hackeng; Eric P A van Dongen; René J Wiezer; Bert van Ramshorst; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2014-10-12       Impact factor: 2.953

Review 8.  Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.

Authors:  Annette S Gross; Anya C Harry; Christine S Clifton; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2022-02-17       Impact factor: 3.716

9.  Pharmacokinetics of enoxaparin in COVID-19 critically ill patients.

Authors:  Paul Jacques Zufferey; Annabelle Dupont; Julien Lanoiselée; Anne Bauters; Julien Poissy; Julien Goutay; Laurent Jean; Morgan Caplan; Lionel Levy; Sophie Susen; Xavier Delavenne
Journal:  Thromb Res       Date:  2021-07-21       Impact factor: 3.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.